US at a glance
- Population
- 341.8 million 2025
- Life expectancy at birth
- 78.9 years, 2024
- People aged 65 and over
- 18.4 % of people, 2025
- Health spending per person
- 13,473 US$ per person, 2023
- Doctors
- 3.68 per 1,000 people, 2022
Updated
Reviewed by Chandani Patel
US Point-of-Care Molecular Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Test, Technology, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.74 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $1.56 Bn | — | — |
| 2025 (base) | $1.69 Bn | +$128.0 Mn | — |
| 2026 (forecast) | $1.83 Bn | +$138.5 Mn | +8.2% |
| 2027 (forecast) | $1.98 Bn | +$149.9 Mn | +17.1% |
| 2028 (forecast) | $2.14 Bn | +$162.2 Mn | +26.7% |
| 2029 (forecast) | $2.32 Bn | +$175.5 Mn | +37.1% |
| 2030 (forecast) | $2.50 Bn | +$189.8 Mn | +48.3% |
| 2031 (forecast) | $2.71 Bn | +$205.4 Mn | +60.5% |
| 2032 (forecast) | $2.93 Bn | +$222.2 Mn | +73.6% |
| 2033 (forecast) | $3.17 Bn | +$240.5 Mn | +87.9% |
| 2034 (forecast) | $3.43 Bn | +$260.2 Mn | +103.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $1.69 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $3.43 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 8.2% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Test, technology and end user (see all) |
| Key players | Cepheid, Abbott Laboratories, Roche Diagnostics, bioMérieux SA, Visby Medical (see all) |
| Regulator in the US | FDASource: US Food and Drug Administration. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Point-of-care molecular diagnostics run PCR and similar DNA tests near the patient, giving lab-quality results in minutes.
Key segments of the point-of-Care Molecular Diagnostics market include test (Respiratory Infections, Sexually Transmitted Infections and Hospital Infections) and technology (PCR and Isothermal Amplification).
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the point-of-Care Molecular Diagnostics market.
Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the point-of-Care Molecular Diagnostics market room to grow, especially in emerging markets.
Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the point-of-Care Molecular Diagnostics market.
The point-of-Care Molecular Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2]
[1] US Food and Drug Administration. Checked 14 Nov 2026.
[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how point-of-Care Molecular Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in the US.
What doctors and scientists are doing in Point-of-Care Molecular Diagnostics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.
From our blog
US · 2 shared keywords
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US
US
Digital Health · US
Healthcare Services · US
Healthcare Services · US
Pharmaceuticals · US
Healthcare Services · US
Healthcare Services · US